AIWiredabout 2 hours ago
Anthropic IPO Filing Tones Down Biology Claims
3 min read
Anthropic's IPO filing states the company lacks experience in physical experimentation and warns that AI-driven drug discovery faces lengthy, costly, and uncertain regulatory pathways. CEO Dario Amodei previously predicted cures within five to 10 years, but the document acknowledges potential pitfalls and the need for test tube and animal trials before human testing.
Level
Hype check
Tap to vote and see what everyone thinks.
In this storyAnthropic
